Adiponectin and hypertension: A putative link between adipocyte function and atherosclerotic risk?

Journal of Human Hypertension

Volumn 21, Issue 1, 2007, Pages 1-4

  Patel, J V ^a   Lim, H S ^a   Hughes, E A ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CANNABINOID RECEPTOR; CREACTIVE PROTEIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ADIPOCYTE; ADIPOSE TISSUE; ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE MEASUREMENT; BODY FAT DISTRIBUTION; BODY MASS; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CYTOKINE PRODUCTION; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONHUMAN; NOTE; OBESITY; PULSE WAVE; RISK ASSESSMENT; STROKE; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADIPOCYTES; ADIPONECTIN; ATHEROSCLEROSIS; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; RISK FACTORS;

EID: 33845518639     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002078     Document Type: Note

References (50)

1. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C, American Heart Association; National Heart, Lung and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
3. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
4. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
5. Alberti KGMM, Zimmet P, Shaw J for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-1062.
6. Lim HS, Patel JV, Lip GYH. Metabolic syndrome: A definition in progress. Circulation 2004; 110: E35.
7. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163: 427-436.
8. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109: 42-46.
9. Matsuzawa S. Therapy insight: Adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3: 35-42.
10. Maeda K, Okubo K, Shimomura I, Mizuno K, Matsubara K. Analysis of expression profile of genes in the human adipose tissue. Gene 1997; 190: 227-235.
11. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lypodystrophy. J Clin Invest 2002; 109: 1345-1350.
12. Moitra J, Manson MM, Olive M, Krylov D, Gavrilova O, Marcus-Sauels B et al. Life without white fat: A transgenic mouse. Genes Dev 1998; 12: 3168-3181.
13. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
14. Tong J, Fujimoto WY, Kahn SE, Weigle DS, McNeely MJ, Leonetti DL et al. Insulin, C-peptide, and leptin concentrations predict increased visceral adiposity at 5- and 10-year follow-ups in nondiabetic Japanese Americans. Diabetes 2004; 54: 985-990.
15. Schutte R, Huisman HW, Schutte AE, Malan NT. Leptin is favourably associated with vascular function in obese Caucasians, but not in obese Africans. J Hum Hypertens 2005; 19(12): 933-939.
16. Schutte R, Huisman HW, Schutte AE, Malan NT. Leptin is independently associated with systolic blood pressure, pulse pressure and arterial compliance in hypertensive African women with increased adiposity: The POWIRS study. J Hum Hypertens 2005; 19(7): 535-541.
17. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al. Paradoxical decrease of an adiposespecific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
18. Balagopal P, George D, Yarandi H, Funanage V, Bayne E. Reversal of obesity-related hypoadiponectinaemia by lifestyle intervention - a controlled randomised study in obese adolescents. J Clin Endocrinol Metab 2005; 90: 6192-6197.
19. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996; 16: 368-374.
20. Winkler G, Cseh K, Baranyi E, Melczer Z, Speer G, Hajos P et al. Tumor necrosis factor system in insulin resistance in gestational diabetes. Diabetes Res Clin Pract 2002; 56: 93-99.
21. Chu N-F, Spiegelmann D, Hotamisligil GS, Rifai N, Stampfer M, Rimm EB. Plasma insulin, leptin, and soluble TNF receptor levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 2001; 157: 495-503.
22. Chu NF, Shen MH, Wu DM, Shieh SM. Plasma TNF-R1 and insulin concentrations in relation to leptin levels among normal and overweight children. Clin Chem 2002; 35: 287-292.
23. Bullo M, Garcia-Lorda P, Megais I, Salas-Salvado J. Systemic inflammation, adipose tissue tumour necrosis factor, and leptin expression. Obes Res 2003; 11: 525-531.
24. Mendall MA, Patel P, Asante M, Ballam L, Morris J, Strachan DP et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997; 78: 273-277.
25. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
26. Adamczak M, Wiêcek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003; 6: 72-75.
27. Lim HS, Tayebjee MH, Tan KT, Patel JV, MacFadyen RJ, Lip GYH. Serum adiponectin in coronary heart disease: Ethnic differences and relation to coronary artery disease severity. Heart 2005; 91: 1605-1606.
28. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation and low plasma concentration precedes a decrease in whole body insulin sensitivity in humans. Diabetes 2002; 51: 1884-1888.
29. Gil-Campos M, Canete R, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004; 23: 963-974.
30. Valsamakis G, Chetty R, McTernan PG, Al-Daghri NM, Barnett AH, Kumar S. Fasting serum adiponectin concentration is reduced in Indo-Asian subjects and is related to HDL cholesterol. Diabetes Obes Metab 2003; 5: 131-135.
31. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953.
32. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-2010.
33. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S et al. Adiponectin in essential hypertension. J Nephrol 2002; 15: 507-511.
34. Mahmud A, Feely J. Adiponectin and arterial stiffness. Am J Hypertens 2005; 18: 1543-1548.
35. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K et al. Hypoadiponectinaemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-1323.
36. Mahmud A, Feely J. Adiponectin and arterial stiffness. Am J Hypertens 2005; 18: 1543-1548.
37. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
38. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234.
39. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H et al. Association of hypoadiponectinaemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234.
40. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: More than just another fat cell hormone? Diabetes Care 2003; 26: 2442-2450.
41. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126-1133.
42. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57-58.
43. Lazzer S, Vermorel M, Montaurier C, Meyer M, Boirie Y. Changes in adipocyte hormones and lipid oxidation associated with weigh loss and regain in severely obese adolescents. Int J Obes 2005; 29: 1184-1191.
44. Despres JP, Golay A, Sjostrom L, Rimonabant in Obesity - Lipis Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidaemia. N Engl J Med 2005; 353: 2121-2134.
45. Baratta R, Amato S, Degano C, Farina MG, Patane G, Vigneri R et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: Evidence from both cross-sectional and interventional studies. J Clin Endocrinol Metab 2004; 89: 2665-2671.
46. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-E751.
47. Xu KT, Ragain RM. Effects of weight status on the recommendations of and adherence to lifestyle modifications among hypertensive adults. J Hum Hypertens 2005; 19(5): 365-371.
48. Schulz M, Liese AD, Boeing H, Cunningham JE, Moore CG, Kroke A. Associations of short-term weight changes and weight cycling with incidence of essential hypertension in the EPIC-Potsdam Study. J Hum Hypertens 2005; 19(1): 61-67.
49. Cook NR, Kumanyika SK, Cutler JA, Whelton PK. Trials of Hypertension Prevention Collaborative Research Group. Dose-response of sodium excretion and blood pressure change among overweight, nonhypertensive adults in a 3-year dietary intervention study. J Hum Hypertens 2005; 19(1): 47-54.
50. Cheung BM, Leung RY, Man YB, Ong KL, Wong LY, Lau CP et al. Association of hypertension with single nucleotide polymorphisms in the quantitative trait locus for abdominal obesity - metabolic syndrome on chromosome 17. J Hum Hypertens 2006; 20(6): 419-425.